ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

STX Shield Therapeutics Plc

2.025
0.025 (1.25%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.025 1.25% 2.025 1.95 2.10 2.025 1.975 2.00 632,383 16:11:13
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 4.47M -40.44M -0.0522 -0.39 15.66M

Shield Therapeutics PLC Notice of Results (1285D)

29/01/2018 7:00am

UK Regulatory


Shield Therapeutics (LSE:STX)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Shield Therapeutics Charts.

TIDMSTX

RNS Number : 1285D

Shield Therapeutics PLC

29 January 2018

Shield Therapeutics plc

("Shield" or the "Group")

Notice of Results

London, UK, 29 January 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs, with an initial focus on addressing anaemia associated with renal and gastrointestinal disorders, announces it will report its results for the year ended 31 December 2017 on Wednesday, 28 February 2018.

Carl Sterritt, Chief Executive Officer and Karl Keegan, Chief Financial Officer, will host a presentation and conference call for analysts at 9.30 a.m. GMT on the morning of the results in the Guildhall Room at 85 Gresham Street, London EC2V 7NQ.

-Ends-

For further information please contact:

 
                                       +44 (0) 207 186 
 Shield Therapeutics plc                8500 
 Karl Keegan, Chief Financial 
  Officer 
  Fleur Wood, Director, Investor 
  Relations 
 Nominated Adviser and Joint           +44 (0)20 3100 
  Broker                                2222 
 Liberum Capital Limited 
 Christopher Britton/Steve Pearce 
                                       + 44 (0)20 7418 
 Joint Broker                           8900 
 Peel Hunt LLP 
 James Steel/Christopher Golden 
                                       +44 (0)203 709 
 Financial PR Adviser                   5700 
 Consilium Strategic Communications    shieldtherapeutics@consilium-comms.com 
  Mary-Jane Elliott/Matthew Neal 
 US Investor Relations                 +1 (212) 867 1762 
 Lazar Partners 
 Fern Lazar/David Carey 
 

About Shield Therapeutics plc

Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru(R), for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORDBGDBGGDBGII

(END) Dow Jones Newswires

January 29, 2018 02:00 ET (07:00 GMT)

1 Year Shield Therapeutics Chart

1 Year Shield Therapeutics Chart

1 Month Shield Therapeutics Chart

1 Month Shield Therapeutics Chart

Your Recent History

Delayed Upgrade Clock